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Abstract
The administration of 1 50 nM etoposide, an inhibitor of
DNA topoisomerase II activity, decreased the
proliferation and induced the differentiation of U937
human promonocytic cells, as determined by nitroblue
tetrazolium reduction, surface accumulation of CD1 1 b/
CD1 8 and CD1 1 c/CD1 8 integrins, and c-hns
protooncogene expression. The expression of these
differentiation markers started to be detected at 24 h of
treatment. Etoposide caused little cell damage, as
determined by trypan blue exclusion and by apoptotic-
like DNA degradation, which was slightly initiated at 48
h. The treatment induced a transient increase in c-fos,
c-jun, and jun B mRNA levels, with maximum values at
1 2 h, a transient increase in collagenase mRNA level,
with maximum value at 48 h, and a progressive increase
in vimentin and lamin A and C mRNAs. These changes
were qualitatively similar to those produced by 12-0-
tetradecanoylphorbol-1 3-acetate. Etoposide also caused
a transient increase of total AP-1 binding activity, with
maximum value at 1 2 h of treatment, as determined by
gel retardation assays. The drug produced an early
transient activation (3-6 h) of membrane-bound protein
kinase C, followed by the later activation (48 h) of both
the membrane and cytosolic enzyme. The protein kinase
C inhibitors, sphinganine and 1 -(5-isoquinolinylsulfonyl)-
2-methylpiperazine (H7), attenuated the induction of
differentiation markers by etoposide. These results
suggest that protein kinase C and AP-1 -dependent gene
expression could be involved in myeloid cell
differentiation by DNA topoisomerase II inhibitors.
Introduction
DNA topoisomerases are enzymes capable of generating
local changes in DNA topology which are required for DNA
replication, transcription, recombination, and chromatid
segregation (1 ). In addition, topoisomerases are the targets
for an important number of antitumor drugs. This is the case
of DNA intercalating agents, such as doxorubicin or amsa-
cnine, and of nonintercalators, such as the epipodophyllo-
toxins etoposide and teniposide. These compounds cause
the stabilization of the cleavable DNA topoisomerase II
covalent complexes, preventing subsequent DNA religation
and producing, as a consequence, DNA strand breaks (2).
Although these breaks are rapidly repaired upon drug re-
moval, the toxic action may be persistent, leading to cell
death (2). In fact, the primary topoisomerase-linked DNA
strand breakage generated by high concentrations of topoi-
somerase inhibitorsmay be rapidly followed by irreversible,
secondary oligonucleosome-sized DNA fragmentation,
which is characteristic of apoptosis (3, 4). Nevertheless, we
and others have demonstrated that topoisomerase II inhib-
itors may also induce the in vitro differentiation of myeloid
cells (5-1 4). This observation is of great importance since it
opens the possibility for the clinical use of antitopoisomer-
ase drugs in differentiation therapies. However, the mech-
anisms responsible for such a differentiation induction are
unknown. Possible explanations are that: (a) the reduction
in topoisomerase II activity is per se a signal or a condition
for differentiation (5, 1 1 , 1 5); (b) differentiation is facilitated
by the perturbations of the cell cycle caused by cytostatic
agents such as antitopoisomerase drugs (1 4); and (C) these
drugs elicit intracellular signals and activate the expression
of genes that are important for differentiation.
The latter hypothesis is examined in the present work by
analyzing the action of subcytotoxic concentrations of eto-
poside on the expression of differentiation markers, the
expression of early protooncogenes and AP-1 -regulated
genes, and the activity of PKC3 in U937 human promono-
cytic cells (1 6). The results are compared with those pro-
duced by TPA, a powerful inducer of differentiation and
PKC activity in this cell line (1 7).
Results
Cell Growth and Differentiation. We measured the effect
of continuous treatments with etoposide on the growth of
U937 cells. At the dose of 1 50 nM the drug progressively
decreased the growth activity, as revealed by cell counting
(Fig. 1 ). The treatment preferentially affected cell transit
throughout G2, as indicated by the accumulation of cells in
this phase of the cycle (Fig. 1).
Alkaline elution assays indicated that a 3-h treatment
with 1 50 nM etoposide sufficed to produce a slight amount
of primary, topoisomerase-linked DNA strand breaks (re-
suits not shown). Nevertheless, secondary DNA degrada-
tion characteristic of apoptosis was only slightly initiated at
the second day of treatment, as observed by electrophoresis
(Fig. 2). In addition, the proportion of nonviable cells,
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Fig. 1. Effect of 1 50 nM etoposide on U937 cell growth and cycle distribu-
tion. The main graph shows the increase in cell number in untreated (O) and
drug-treated (0) cultures. Data are the average of two determinations with
similar results. The insetshows the cell cycle distribution in untreated (dotted
line) and 72-h treated (continuous line) cultures, as determined by flow
cytometry analysis of propidium iodide-stained cells.
-
Fig. 2. DNA degradation following etoposide treatment. DNA extracted
from cells treated with 1 50 nm etoposide for the indicated time periods was
fractionated by agarose gel electrophoresis and visualized by ethidium bro-
mide staining and UV illumination. DNA extracted from cells treated for 24
h with 3 tiM etoposide was also analyzed as a control of apoptotic DNA
degradation. The horizontal lines at the margins indicate the position of
simultaneously run markers (from top to bottom: 4.4, 2.5, 1 .9, 1 .1 , 0.61,
0.45, and 0.27 kb).
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which represented the 4% in untreated cultures, remained
unchanged until the second day and underwent only a
slight increase (1 8%) at the third day of treatment, as mdi-
cated by trypan blue exclusion. Hence, the concentration of
1 50 nM etoposide was considered subcytotoxic and was
adopted for further experiments.
The capacity of etoposide to induce the expression of
myeloid differentiation markers, i.e., the surface accumu-
lation of the CD1 1 b/CD1 8 and CD1 1 c/CD1 8 leukocyte
integrins (18, 19) and the reduction of NBT (20), was after-
wards determined. We also measured the expression at the
RNA level of the c-fms protooncogene, which is a specific
characteristic of the mature monocyte-macrophage pheno-
type (21 ). The phorbol ester TPA was used as a positive
control. The results in Fig. 3 indicate that etoposide in-
creased the expression of all these differentiation markers,
the increase being already observed at 24 h of treatment.
Gene Expression and AP-1 Binding. Northern blot assays
were carried out to analyze the effect of etoposide on the
expression of other genes which might be involved in dif-
ferentiation. This included the c-fos, c-jun, and Jun B pro-
tooncogenes, which encode protein constituents of the
AP-1 transcription factor (22); the collagenase and vimentin
genes, the expression of which is regulated by AP-1 (23,
24); and the A lamin gene, which encodes the nuclear A
and C intermediate filament proteins (25). The results are
represented in Fig. 4. Etoposide caused a transient increase
in c-fos, c-fun, and fun B mRNA levels, which reached the
maximum values at 1 2 h of treatment, to decrease thereaf-
ter. The drug also caused a transient increase in collagenase
mRNA levels, with maximum value at 48 h. Finally, the
levels of vimentin and of lamin A and C mRNAs underwent
a progressive increase (24 h and thereafter). TPA (1 5 nM),
which was included as a positive control, also activated the
expression of those genes, although at earlier times than
etoposide (Fig. 4).
Fig. 5 shows the effect of etoposide on total AP-1 binding
activity, as determined by gel retardation assays. The drug
caused an increase in binding activity, which reached the
maximum value at 1 2 h, to decrease at 48 h to control
levels. An increase in AP-1 binding was already observed at




PKC Activity. Since etoposide and TPA had similar ef-
fects on gene expression and TPA is a potent activator of
PKC, we were interested to measure the possible action of
etoposide on PKC activity. The results are represented in
Fig. 6. An increase in membrane-associated PKC activity
could be detected at 3 and 6 h of treatment, to decrease
again at 1 2 h. By contrast, no significant changes in cyto-
solic PKC activity were observed at these times. At 48 h of
treatment, PKC activity was again increased, affecting both
the membrane-bound and cytosolic fractions.
Effect of PKC Inhibitors. To determine whether PKC ac-
tivation could be effectively involved in differentiation in-
duction by etoposide, experiments using the PKC inhibitors
sphinganmne, 1 -(5-isoquinol inylsulfonyl)-2-methylpipera-
zine (H7), and staurosporine were carried out. Three differ-
ent experimental designs were used (Fig. 7). In the first
design, cells were treated for 48 h with etoposide, either
alone or in the presence ofthe PKC inhibitors (Fig. 7A). This
was aimed at examining the total (early and late) PKC
activation. In the second design, cells were first incubated
for 24 h with etoposide, either alone or in the presence of
the PKC inhibitors, then washed and let to recover for 24 h
























Fig. 3. Time-course expression of differentiation markers. A, percentage of
cells which reduce NBT and express the CD1 lb/CD18 and CD1 lc/CD18
leukocyte integrins at different times of treatment with 1 50 nM etoposide.
Data are the average of two determinations with similar results. Values in
untreated cells were 4% for NBT and 5% for both CD1 1 b/CD1 8 for CD1 1 c/
CD18. Values in TPA-treated cells (24 h at 15 nM) were 65% for NBT, 71%
for CD11b/CD18, and 82% for CD11c/CD18. B, changes in the level of
c-fms mRNA (arrowheads) in cells treated with 1 50 nt,s etoposide or 1 5 nM
TPA. Total cytoplasmic RNA samples (15 pg/lane) were separated by elec-
trophoresis, transferred to nylon membranes, and hybridized with a c-fms-
specific cDNA probe. The position of the 28 5 and 1 8 S ribosomal RNAs is
indicated. Ethidium bromide staining of 28 S ribosomal RNA in the gel is
shown as a control of sample loading.











specifically examine the early activation of membrane-
bound PKC activity. In the third design, cells were incu-
bated for 24 h with etoposide alone and then for 24 h more
with etoposide either alone or in the presence of the PKC
inhibitors (Fig. 7C). This was aimed at specifically examin-
ing the late activation of PKC activity. As a control, cells
were incubated for 24 h with TPA, either in the absence or
in the presence of the PKC inhibitors (Fig. 7D). The ob-
tamed results are expressed in Table 1 . It was found that
sphinganmne and H7 attenuated the etoposide-mediated in-
duction of the CD1 1 b/CD1 8 integnin. By contrast, stauro-
sponine did not attenuate and even potentiated the etopo-
side-mediated induction of this differentiation marker.
Allowing for some quantitative differences, the same results
were obtained when the PKC inhibitors were applied for the
total 48 h or the partial 24-h treatment periods. The three




Fig. 4. Effect of etoposide and TPA on specific mRNA levels. Total cyto-
plasmic RNA was analyzed by Northern blot. A filter was successively
hybridized with c-los, c-jun, and Jun B-specific probes, another one with
vimentin and lamin probes, and a third one with a collagenase probe. All
other conditions were as in Fig. 3B. The c-jun-specific probe recognized two
mRNA species of 3.4 and 2.7 kb. The lamin-specific probe recognized two
mRNA species of 3.0 and 2.0 kb corresponding to lamins A and C, respec-
tively.
the differentiation marker, which is in agreement with ear-
lien published observations (26, 27). At the concentrations
used, none of the PKC inhibitors caused significant cell
mortality (more than 90% of the cells excluded trypan blue
at 48 h of treatment). Sphinganine and H7 did not alter the
basal level of CD1 1 b/CD1 8 expression, but staurosporine
slightly activated the expression of this marker at 48 h of
treatment (Table 1).
Discussion
The results in this work indicated that subcytotoxic concen-
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Fig. 6. Effect of etoposide on PKC activity. The graphs represent the mem-
brane-bound and cytosolic PKC activities at different times of treatment with
1 50 ns etoposide. Points, mean of two determinations; bars, SD.
induced the differentiation of U937 promonocytic cells,
also caused the activation of AP-1-regulated gene expres-
sion. This was demonstrated by measuring total AP-1 bind-
ing activity as well as the expression of individual genes.
Some of these genes could be important for the acquisition
of the mature phenotype, as we had earlier demonstrated in
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Fig. 7. Experimental designs used to determine the effect of PKC inhibitors
(H7, sphinganine, and staurosporine) on the etoposide- and TPA-induced
expression of CD1 1 b/CD1 8. Design A was aimed at examining the total
(early plus late) PKC activation (see Fig. 6), while the early and the late
enzyme activations were separately examined in Designs B and C, respec-
tively. As a control, the effect of the PKC inhibitors was also examined in
TPA-treated cells (Design 0). The results are indicated in Table 1.
fun B (1 2 h) preceded the expression of differentiation
markers (24 h) and then could be involved in the trigger of
differentiation. In fact, it is known that these early protoon-
cogenes may be implicated in the activation of diverse
cellular processes such as proliferation, differentiation (22),
and apoptosis (29). In an earlier work, Rubin et a!. (30)
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Fig. 5. Effect of etoposide on
AP-1 binding activity. Nuclear ex-
tracts from cells treated for the in-
dicated time periods with either
1 50 nM etoposide (A) or 1 5 nM TPA
(B) were analyzed by gel retarda-
tion assay for AP-1 binding. The
AP-1 -specific signal in these assaysP was totally suppressed by the pres-
. ence of 1 00-fold molar excess of
 .  specific competitor (not shown). C,
nuclear extracts from cells treated
for 6 h with TPA were assayed for
AP-1 binding in the absence of
competitor I -C), in the presence of
100-fold molar excess of nonspe-
cific competitor (+NSC), and in
the presence of different amounts
(from 100- to 5-fold molar excess)
ofspecificcompetitor(+SC), as in-
dicated in “Materials and Meth-
ods.” The position of free oligo-
probe (arrow) and oligoprobe-
AP-1 complexes (arrowhead) are
indicated.
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Table 1 Effect of PKC inhibitors, etoposide, and TPA on CD1 1 b/CD1 8
surface integrin expression
A, B, and C correspond to the experimental designs in Fig. 7. Values represent
the mean ± SD of at least three determinations. Sphinganine (SPH) was used at
5 M, H7 at 100 M, staurosporine (Si) at 4 nm, etoposide at 1 50 nm, and TPA
at 3 nm. Exp., Experimental.
Exp. Positive
. Treatmentdesign cells ( /o)




A Etoposide 40 ± 2.3
Etoposide + SPH 1 7 ± 2.8
Etoposide + H7 21 ± 2.4
Etoposide + ST 50 ± 3.3
B Etoposide 32 ± 1.9
Etoposide + SPH 1 1 ± 0.9
Etoposide + H7 15 ± 2.1
C Etoposide 42 ± 4.1
Etoposide + SPH 24 ± 1.8
Etoposide + H7 27 ± 2.2
D TPA 53±6.0
TPA + SPH 31 ± 3.6
TPA+H7 23±3.2
TPA+ST 9±2.2
showed that etoposide activated c-fos and c-jun expression
in HL-60 human promyelocytic cells. However, the drug
was used at highly toxic concentrations, which rapidly
provoked oligonucleosome-sized DNA degradation.
Hence, it is possible that c-los and c-jun could be mainly
regulating the trigger of apoptotic cell death. Our expeni-
ments do not clearly allow the separation of events leading
to differentiation from those regulating apoptosis. Never-
theless, the fact that at the subcytotoxic concentrations of
etoposide used apoptotic-like DNA fragmentation was only
slightly initiated at 48 h of treatment might indicate that
c-los and c-jun were preferentially signaling cell differenti-
ation instead of cell death.
The possibility that PKC could be involved in differenti-
ation by antitopoisomenase drugs was earlier suggested by
the observations of Constantinou et a!. (5), which indicated
that the nonspecific topoisomerase II inhibitor Novobiocin
caused differentiation of TPA-sensitive but not of TPA-re-
sistant HL-60 cells and that the PKC inhibitor H7 prevented
the Novobiocin-induced differentiation. Our results directly
demonstrated that differentiation of U937 cells by etopo-
side is accompanied by the activation of PKC. The treatment
caused and early transient activation (3-6 h) of membrane-
bound PKC, which was followed by a late activation (48 h)
oftotal, membrane-bound plus cytosolic enzyme. The early
PKC activation preceded and then could be involved in the
activation of early protooncogene expression (1 2 h) and the
trigger of differentiation (24 h). The late activation of total
enzyme, which has currently been observed with other
differentiation inducers (31, 32), might be required for the
achievement of the differentiated phenotype (32). The fact
that the etoposide-induced expression of differentiation
markers was reduced when the PKC inhibitors H7 and
sphinganine were applied for discrete time periods con-
firmed that both the early and late activation of PKC were
important for differentiation. It could be surprising that the
PKC inhibitor staurosponine potentiated the action of eto-
poside, although it inhibited differentiation by TPA. The
action of staurosponine seems to depend on the inducer
used, since it was also found to potentiate differentiation by
la,25-dihydroxyvitamin D3 and retinoic acid, which acti-
vate PKC, while decreasing differentiation by TPA in HL-60
cells (27). Such a discrepancy may be explained by differ-
ences in the signaling pathways elicited by TPA and the
other inducers as well as by the poor specificity of action of
the protein kinase inhibitors(33).
Our results give rise to several questions. One of them
concerns the mechanism by which etoposide, the primary
target of which are the topoisomerase-DNA complexes,
rapidly activated membrane-bound PKC. A possible expla-
nation is that the limited amount of primary DNA strand
breakage, resulting from topoisomerase-DNA complex sta-
bilization, could itself elicit PKC activation throughout yet
unknown pathways. In this regard, Radler-PohI et a!. (34)
suggested that DNA damage could be the primary step
signaling other cellular events, such as activation of cyto-
plasmic protein kinases and stimulation of AP-1 activity, in
UV-irradiated cells. Another explanation is that PKC could
be activated as a consequence of nonspecific membrane
perturbations, since epipodophyllotoxins (etoposide and te-
niposide) are known to interact with membrane lipids and
alter membrane fluidity (35). Experiments using topoi-
somerase II inhibitors which do not cause topoisomerase-
DNA cleavable complex stabilization nor primary DNA
strand breakage are in progress to investigate this problem.
Another question is the reason for the temporal dissoci-
ation between the early activation of membrane-bound
PKC, observed at 3 h, and the maximum AP-1 binding
activity, detected at 1 2 h. It is believed that PKC may induce
AP-1 activation by both pre- and posttranslational mecha-
nisms. For instance, Boyle eta!. (36) proposed that the rapid
AP-1 activation by TPA in some epithelial and fibroblastic
cells could be due to decreased phosphorylation at specific
sites of pre-existing c-jun, resulting in an enhanced DNA
binding activity. By contrast, AP-1 activation at prolonged
times of treatment could be due to new synthesis of c-los
and c-jun. As indicated by the same authors, the importance
of the former, posttranslational mechanism would be neg-
ligible in cell types in which the basal levels of c-jun are
very low. If this is the case in nonstimulated U937 cells,
AP-1 activation could only occur at the expense of new
production of c-los and c-jun, which under our condi-
tions was detected at the RNA level at 1 2 h of etoposide
treatment.
Materials and Methods
Cell Culture and Drug Treatment. U937 cells were grown
in RPMI 1 640 supplemented with 1 0% heat-inactivated
fetal calf serum, 5 mM 4-(2-hydroxyethyl)-1 -pipera-
zineethanesulfonic acid buffer, and 0.2% sodium bicarbon-
ate in a humidified 5% CO2 atmosphere at 37#{176}C.TPA,
etoposide, DL-sphinganine, staurosponine, and H7 were ob-
tamed from Sigma Qulmica, Madrid, Spain. TPA and eto-
poside were dissolved in dimethyl sulfoxide at 1 .5 and 20
mM, respectively, sphinganine at 1 0 mM in ethanol, and H7
and staurosponine at 1 mtit in distilled water. The solutions
were stored at -20#{176}C.At the final concentrations used, the
solvents were without significant effects on cell growth and
differentiation. Cells were seeded for experiments in a mix-
tune of old and fresh media (1 :3, v/v) at i0 cells/mi. Cells
from control cultures were harvested at the exponential
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growth phase. Cells from treated cultures were harvested at
the times indicated in each experiment. To prevent long-
term cultures from reaching plateau densities on nutrient
exhaustion, at the second day of treatment, they were sup-
plemented with an equal volume of fresh medium contain-
ing the corresponding differentiation inducer. Cell growth
and viability were checked using an hemocytometen and
trypan blue exclusion, respectively. Cell cycle distribution
was determined by flow cytometry determinations after
propidium iodide staining, as described earlier (10).
Measurement of Differentiation Markers. The ability of
the cells to reduce NBT was determined by incubating them
for 20 mm at 37#{176}Cin PBS solution containing 0.2% NBT
and 0.1 5 M TPA; then the cells were examined with a
microscope for the presence of formazan precipitates. The
surface expression of CR3 (CD1 1 b/CD1 8) and p150,95
(CD1 1c/CD1 8) leukocyte integnins was determined by in-
direct immunofluonescence combined with flow cytometry,
as it was described in a previous work (10).
Determination of Apoptotic DNA Degradation. Cells
(1 06) were washed with PBS, resuspended in 100 p1 of 45
mM Tnis-borate buffer (pH 8.0) containing 0.25% Nonidet
P-40 and 0.1% RNase A, and incubated for 1 h at 37#{176}C.
Proteinase K was then added to a final concentration of 1
mg/mI, and the incubation was followed for 1 h more. The
samples were mixed at 70#{176}Cwith 20 p1 of 1 0 mt’i EDTA (pH
8.0) containing 0.25% (v/v) bromophenol blue, 40% su-
crose, and 1% low-melting point aganose; then 25 p1 of the
mixture were electrophoresed in 2% agarose gels contain-
ing 0.5 pg/mI of ethidium bromide. HindIIl-digested 429
DNA was used as a marker.
RNA Blot Assays. Total cytoplasmic RNA was prepared
as described in a previous work (37). RNA samples (15
pg/lane) were denatured, electrophoresed in 1 .1 % agarose-
formaldehyde gels, and blotted to nylon membranes (Hy-
bond-N; Amersham). RNA blots were prehybnidized, hy-
bnidized with excess 32P-labeled probes, washed under
highly stringent conditions, and finally autoradiographed.
The probes used were: the 2.7-kb los-specific XhoI-Ncol
fragment of  clone (38); the 1 .8 plus 0.8-kb
human jun-specific EcoRI-PstI fragments of AH1 1 9 clone
(39); a pGEM-2 plasmid containing the human jun B cDNA
(40); the 1 .1 -kb human vimentin-specific XhoI fragment of
p4Fl clone (41); the 2.0-kb EcoRl fragment of a human C
lamin clone (25); the 2.0-kb human collagenase-specific
Hindlll-SmaI fragment of pCllase 1 clone (Ref. 42; Amen-
can Type Culture Collection); and the 1 .2-kb human Ims-
specific EcoRI fragment of pcfms 1 04 clone (Ref. 43; Amen-
ican Type Culture Collection). The fragments were labeled
to approximately 10 cpm/pg of DNA with [a-32P]dCTP
(3000 Ci/mmol; New England Nuclear, Boston, MA) by
random hexanucleotide priming (44).
AP-1 Binding Assays. Nuclear extracts from 2 X 10 cells
were prepared according to the method of Schneibert et a!.
(45) and stored at -70#{176}C.The partially complementary
oligonucleotides 5’-GGCTAGTGATGAGTCAAGCCG-
GATC-3 ‘ and 5’-GGGATCCGGCTTGACTCATCACTAG-
3’, synthesized in a Gene Assembler Plus (Pharmacia LKB,
Uppsala, Sweden), were used to prepare a double-strand
oligonucleotide containing an AP-1 -recognizing sequence
(AP-1 probe). This oligonucleotide was labeled with
[a-32P]dCTP following the method of Sambrook et a!. (46).
The oligonucleotides 5’-GCGAAACCCCTGGAATATTC-
CCGACCTGGC-3’ and 5’-GGGCCAGGTCGGGAATAT-
TCCAGGGG1TFCG-3’ were used to prepare a double-
strand oligonucleotide which contained a heat-shock
element, recognized by the heat-shock transcription factor
(HSE probe). Binding reactions were carried out for 1 5 mm
at room temperature in 20 p1 of binding buffer [25 mt’i
NaCI, 60 mM KCI, 2 mti dithiothneitol, 2% Ficoll, 0.01%
(v/v)Nonidet P-40, 0.1 mg/mI bovine serum albumin, and
25 mti 4-(2-hydroxyethyl)-1 -pipenazineethanesulfonic acid
(pH 7.4)1 containing 5 ng ofthe labeled AP-1 probe, 8 pg of
total nuclear proteins, 2 pg of poly(dI:dC), and 2 pg salmon
sperm DNA. When required, unlabeled AP-1 on HSE probes
were added as specific and nonspecific competitors, re-
spectively. The samples were electrophonesed in 4% poly-
acrylamide gels, and the gels were dried and autonadio-
graphed.
Protein Kinase C Assays. Cells (5 X 1 06) were collected,
washed with PBS, and suspended in 0.4 ml ice-cold extrac-
tion buffer [20 mM Tnis-HCI (pH 7.5) containing 0.5 mtvi
EDTA, 0.5 mM EGTA, 25 pg/mI aprotinin, and 25 pg/mI
leupeptin). The cells were disrupted with a Dounce homog-
enizen, after which the homogenates were first centrifuged
for 2 mm in a microfuge to remove the cellular debris and
then in an ultracentnifuge for 30 mm at 1 00,000 X g. The
supernatants (cytosolic fractions) were kept at 4#{176}Cuntil
used. The pellets (membrane fractions) were resuspended in
extraction buffer containing 0.5% Triton X-1 00 and kept for
30 mm on ice with occasional vortexing, after which they
were centrifuged for 10 mm in a microfuge to collect the
supennatants. The cytosolic fractions and the detergent-
extracted membrane fractions were eluted at 4#{176}Cwith 2 ml
elution buffer [20 mM Tnis-HCI (pH 7.5) containing 0.5 mti
EDTA, 0.5 mM EGTA, 0.2 M NaCI, and 10 mti f3-mencap-
toethanol] in Sepharose 2B columns. PKC activities were
determined with the Protein Kinase C Assay System
(GIBCO/BRL, Grand Island, NY), according to the instruc-
tions described by the manufacturer. This assay system
follows the procedure described by Yasuda et a!. (47),
which uses as phosphate acceptor the myelin basic protein
sequence Gln-Lys-Arg-Pno-Sen-Gln-Ang-Ser-Lys-Tyr-Leu
(MBP4_14), and is considered to be highly specific for the
PKC-a, PKC-3, and PKC-’y subspecies.
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